0000000000125167

AUTHOR

Alain Monnereau

showing 39 related works from this author

Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project

2014

Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy and the fifth most common type of cancer in more developed regions of the world (1). Numerous NHL subtypes with distinct combinations of morphologic, immunophenotypic, genetic, and clinical features are currently recognized (2,3). The incidence of NHL subtypes varies substantially by age, sex, and race/ethnicity (4–7). However, the etiological implications of this biological, clinical, and epidemiological diversity are incompletely understood. The importance of investigating etiology by NHL subtype is clearly supported by research on immunosuppression, infections, and autoimmune diseases, which are the strongest and most e…

AdultMaleCancer ResearchAdolescentChronic lymphocytic leukemiaFollicular lymphomaComorbidityDiseaseNon-Hodgkin lymphoma (NHL)ArticleYoung AdultRisk Factorsimmune system diseasesOccupational Exposurehemic and lymphatic diseasesOdds RatiomedicineCluster AnalysisHumansRisk factorFamily historyLife StyleAgedAged 80 and overInternational Lymphoma Epidemiology Consortium (InterLymph)business.industryLymphoma Non-HodgkinAustraliaCase-control studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLymphomaEuropeOncologyCase-Control StudiesNorth AmericaImmunologyFemalebusinessJNCI Monographs
researchProduct

Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project

2014

Background: Non-Hodgkin lymphoma (NHL), the most common hematologic malignancy, consists of numerous subtypes. The etiology of NHL is incompletely understood, and increasing evidence suggests that risk factors may vary by NHL subtype. However, small numbers of cases have made investigation of subtype-specific risks challenging. The International Lymphoma Epidemiology Consortium therefore undertook the NHL Subtypes Project, an international collaborative effort to investigate the etiologies of NHL subtypes. This article describes in detail the project rationale and design. Methods: We pooled individual-level data from 20 case-control studies (17 471 NHL cases, 23 096 controls) from North Ame…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyAdolescentChronic lymphocytic leukemiaFollicular lymphomaNon-Hodgkin lymphoma (NHL)ArticleLymphoplasmacytic LymphomaYoung AdultRisk Factorsimmune system diseaseshemic and lymphatic diseasesInternal medicineEpidemiology of cancerPrevalencemedicineHumansAgedAged 80 and overMycosis fungoidesbusiness.industryLymphoma Non-HodgkinAustraliaWaldenstrom macroglobulinemiaGeneral MedicineMiddle Agedmedicine.diseaseNon-Hodgkin's lymphomaEuropeOncologyCase-Control StudiesEpidemiologic Research DesignNorth AmericaImmunologyInternational Lymphoma Epidemiology Consortiumhematologic malignancyFemaleMantle cell lymphomabusinessJNCI Monographs
researchProduct

Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes

2016

International audience; Evidence from a small number of studies suggests that longer telomere length measured in peripheral leukocytes is associated with an increased risk of non-Hodgkin lymphoma (NHL). However, these studies may be biased by reverse causation, confounded by unmeasured environmental exposures and might miss time points for which prospective telomere measurement would best reveal a relationship between telomere length and NHL risk. We performed an analysis of genetically inferred telomere length and NHL risk in a study of 10 102 NHL cases of the four most common B-cell histologic types and 9562 controls using a genetic risk score (GRS) comprising nine telomere length-associa…

0301 basic medicineSerumMaleLymphomaanalysisChronic lymphocytic leukemiaFollicular lymphomaGlobal Health[ SDV.CAN ] Life Sciences [q-bio]/Cancerimmunologysurgery0302 clinical medicineEndocrinologyimmune system diseasessingle nucleotide polymorphismGermanyhemic and lymphatic diseasesLondon80 and overOdds RatiogeneticsProspective StudiesB-cell lymphomaAssociation Studies ArticleGenetics (clinical)Aged 80 and overeducation.field_of_studytelomereGenomeLeukemiaAge FactorsGeneral MedicineEnvironmental exposureGenomicsMiddle Agedb-cell lymphomasmall cell lymphomaItaly030220 oncology & carcinogenesisMedicineepidemiologyFemaleFranceRisk of B-cell lymphoma subtypesRiskAdultCanadaChinaLymphoma B-CellGenotypeAdolescentleukocytesetiologyPopulationPopulation[SDV.CAN]Life Sciences [q-bio]/CancerBiologyEnvironmentRisk AssessmentmethodsTime03 medical and health sciencesmedicineHumansFamilyGenetic Predisposition to DiseaseeducationMolecular BiologyAllelesOccupational HealthGenetic Association StudiesAgedB-CellInternational AgenciesOdds ratioEnvironmental Exposuremedicine.diseaseTelomereNon-Hodgkin's lymphoma030104 developmental biologyImmunologyphysiologyChronic DiseasepathologyLaboratoriesmetabolism
researchProduct

Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia

2013

Genome-wide association studies (GWAS) have previously identified 13 loci associated with risk of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL). To identify additional CLL susceptibility loci, we conducted the largest meta-analysis for CLL thus far, including four GWAS with a total of 3,100 individuals with CLL (cases) and 7,667 controls. In the meta-analysis, we identified ten independent associated SNPs in nine new loci at 10q23.31 (ACTA2 or FAS (ACTA2/FAS), P = 1.22 × 10-14), 18q21.33 (BCL2, P = 7.76 × 10-11), 11p15.5 (C11orf21, P = 2.15 × 10 -10), 4q25 (LEF1, P = 4.24 × 10-10), 2q33.1 (CASP10 or CASP8 (CASP10/CASP8), P = 2.50 × 10-9), 9p21.3 (CDKN2B-AS1, P = 1.27 × 10…

RiskLinkage disequilibriumChronic lymphocytic leukemiaSingle-nucleotide polymorphismLocus (genetics)Genome-wide association studyBiologyPolymorphism Single NucleotideLinkage DisequilibriumArticleGeneticsmedicineHumansGenetic Predisposition to DiseaseLeucèmia limfocítica crònicaGenome-wide association studies (GWAS)B-cell lymphomachronic lymphocytic leukemia or small lymphocytic lymphoma (CLL)Genetic associationRecombination GeneticGeneticsGenomicsmedicine.diseaseLeukemia Lymphocytic Chronic B-CellGenòmicaLeukemiaGenetic LociCase-Control StudiesChromosomes Human Pair 2Chronic lymphocytic leukemiaGenome-Wide Association Study
researchProduct

Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic st…

2017

IF 7.702; International audience; The survival of patients with diffuse large B-cell lymphoma has increased during the last decade as a result of addition of anti-CD20 to anthracycline-based chemotherapy. Although the trend is encouraging, there are persistent differences in survival within and between the USA and European countries suggesting that non-biological factors play a role. Our aim was to investigate the influence of such factors on relative survival of patients with diffuse large B-cell lymphoma. We conducted a retrospective, multicenter, registry-based study in France on 1165 incident cases of diffuse large B-cell lymphoma between 2002 and 2008. Relative survival analyses were p…

[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/HematologyMale0301 basic medicinePediatricsMultivariate analysisMESH: RegistriesMESH : AgedMESH: ComorbidityComorbidityMESH : Lymphoma Large B-Cell DiffuseMESH: Aged 80 and over0302 clinical medicineInternational Prognostic IndexMESH : ChildMESH: ChildMESH : Population Surveillance[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleRegistriesYoung adultChildAged 80 and overMESH: AgedMESH: Middle AgedMESH : PrognosisRelative survivalMESH: Patient Outcome Assessment[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyArticlesHematologyMiddle AgedMESH : AdultPrognosisMESH : Patient Outcome Assessment3. Good healthMESH: Young AdultPopulation SurveillanceMESH: Survival Analysis030220 oncology & carcinogenesisMESH : ComorbidityMarital statusFemaleFranceLymphoma Large B-Cell DiffuseNon-Hodgkin LeukemiaAdultmedicine.medical_specialtyAdolescentMESH : MaleMESH: Factor Analysis StatisticalMESH : Young AdultMESH : Factor Analysis StatisticalMESH: PrognosisMESH: Population SurveillanceMESH: Social ClassYoung Adult03 medical and health sciencesMESH : AdolescentInternal medicineMESH : Social ClassmedicineHumansMESH : Middle AgedMESH : Aged 80 and overMESH : FranceSurvival analysisAgedMESH: AdolescentMESH: Humansbusiness.industryMESH : HumansMESH: Adultmedicine.diseaseSurvival AnalysisComorbidityMESH: MalePatient Outcome AssessmentMESH: France030104 developmental biologySocial ClassMESH: Lymphoma Large B-Cell DiffuseMESH : Survival AnalysisFactor Analysis StatisticalbusinessMESH: FemaleDiffuse large B-cell lymphomaMESH : RegistriesHaematologica
researchProduct

Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference

2019

Germ-cell tumours (GCT) of the testis and penile squamous cell carcinoma (PeSCC) are a rare and a very rare uro-genital cancers, respectively. Both tumours are well defined entities in terms of management, where specific recommendations - in the form of continuously up-to-dated guide lines- are provided. Impact of these tumour is relevant. Testicular GCT affects young, healthy men at the beginning of their adult life. PeSCC affects older men, but a proportion of these patients are young and the personal consequences of the disease may be devastating. Deviation from recommended management may be a reason of a significant prognostic worsening, as proper treatment favourably impacts on these t…

OncologyMaleSurvival030232 urology & nephrologyDiseaseCarcinoma; Community network; Europe; Germ cell and embryonal; Neoplasms; Penis neoplasms; Rare diseases; Squamous cell; Survival; Tertiary care centres; Testicular neoplasms; Surgery; Oncology0302 clinical medicineNeoplasmsEpidemiologyTesticular neoplasmReferral and ConsultationPenis neoplasmsCarcinoma ; Community network ; Europe ; Germ cell and embryonal ; Neoplasms ; Penis neoplasms ; Rare diseases ; Squamous cell ; Survival ; Tertiary care centres ; Testicular neoplasmsGeneral MedicineNeoplasms Germ Cell and EmbryonalTertiary care centreRare diseasesSurvival RateEuropeOncology030220 oncology & carcinogenesisLymphatic MetastasisCarcinoma Squamous CellHumanmedicine.medical_specialtyTesticular neoplasmsPenile squamous cell carcinomaGerm cell and embryonalCommunity networkSocio-culturaleCancer Care FacilitiesTertiary care centres03 medical and health sciencesPenis neoplasmRare DiseaseInternal medicinemedicineCarcinomaHumansPenile NeoplasmsNeoplasm StagingPenis Neoplasmsbusiness.industryCancer Care FacilitieSquamous cellCarcinomaLymphatic Metastasimedicine.diseaseTesticular germ cellAdult lifePenile NeoplasmProper treatmentNeoplasmLymph Node ExcisionSurgerybusinessDelivery of Health Care
researchProduct

Epidemiology of rare cancers and inequalities in oncologic outcomes

2019

Rare cancers epidemiology is better known compared to the other rare diseases. Thanks to the long history of the European population-based cancer registries and to the EUROCARE huge database, the burden of rare cancers has been estimated the European (EU28) population. A considerable fraction of all cancers is represented by rare cancers (24%). They are a heterogeneous group of diseases, but they share similar problems: uncertainty of diagnosis, lack of therapies, poor research opportunities, difficulties in clinical trials, lack of expertise and of centres of reference. This paper analyses the major epidemiological indicators of frequency (incidence and prevalence) and outcome (5-year surv…

0301 basic medicineMaleSettore MED/06 - Oncologia Medica0302 clinical medicineNeoplasmsEpidemiologyPrevalenceEurope ; Population-based cancer registry ; Rare cancersChildeducation.field_of_studyRelative survivalIncidence (epidemiology)IncidenceGeneral MedicineMiddle AgedSurvival RateEuropeHealthcare DisparitieOncology030220 oncology & carcinogenesisChild PreschoolFemaleHumanAdultmedicine.medical_specialtyAdolescentEurope; Population-based cancer registry; Rare cancers; Surgery; OncologyPopulationSocio-culturaleEurope Population-based cancer registry Rare cancers03 medical and health sciencesYoung AdultRare DiseasesAge DistributionRare DiseasemedicineHumansRare cancersHealthcare DisparitiesSex DistributioneducationPopulation-based cancer registrySurvival rateAgedbusiness.industryPublic healthInfant NewbornCancerRare cancerInfantmedicine.diseaseClinical trial030104 developmental biologyNeoplasmSurgerybusinessDemography
researchProduct

Exposure to UV radiation and risk of Hodgkin lymphoma: A pooled analysis

2013

Ultraviolet radiation (UVR) exposure has been inversely associated with Hodgkin lymphoma (HL) risk, but only inconsistently, only in a few studies, and without attention to HL heterogeneity. We conducted a pooled analysis of HL risk focusing on type and timing of UVR exposure and on disease subtypes by age, histology, and tumor-cell Epstein-Barr virus (EBV) status. Four case-control studies contributed 1320HLcasesand 6381 controls. We estimated lifetime, adulthood, and childhood UVR exposure and history of sunburn and sunlamp use. We used 2-stage estimation with mixed-effects models and weighted pooled effect estimates by inverse marginal variances. We observed statistically significant inv…

OncologyMaleEpstein-Barr Virus InfectionsDNA RepairSunburnSkin PigmentationComorbidityBiochemistryT-Lymphocytes Regulatoryvisual_art.visual_artistimmune system diseaseshemic and lymphatic diseasesYoung adultSunburnAged 80 and overLymphoid NeoplasiaSunbathingintegumentary systemExposure CategoryInside BLOODConfoundingAge FactorsConfounding Factors EpidemiologicHematologyMiddle AgedHodgkin DiseaseEuropeHodgkin lymphoma (HL)visual_artSunlightFemaleAdultmedicine.medical_specialtyAdolescentUltraviolet RaysImmunologyBiologyWhite PeopleYoung AdultSunbathingInternal medicinemedicineHumansUltraviolet radiation (UVR)tumor-cell Epstein-Barr virus (EBV)AgedfungiCase-control studyModels ImmunologicalDose-Response Relationship RadiationCell BiologyOdds ratiomedicine.diseaseRelative riskCase-Control StudiesImmunologyDNA Damage
researchProduct

Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991–2010 (Automated Childhood Cancer Informatio…

2018

List of ACCIS contributors = Monika Hackl, Anna Zborovskaya, Nadya Dimitrova, Zdravka Valerianova, Ladislav Dušek, Margit Mägi, Alain Monnereau, Jacqueline Clavel, Michel Velten, Anne-Valérie Guizard, Véronique Bouvier, Xavier Troussard, Anne-Sophie Woronoff, Emilie Marrer, Brigitte Trétarre, Marc Colonna, Olivier Ganry, Pascale Grosclaude, Berndt Holleczek, Zsuzsanna Jakab, Laufey Tryggvadóttir, Lucia Mangone, Franco Merletti, Stefano Ferretti, Bianca Caruso, Maria Michiara, Rosario Tumino, Fabio Falcini, Roberto Zanetti, Giovanna Tagliabue, Otto Visser, Giske Ursin, Ryszard Mężyk, Kamila Kepska, José Laranja Pontes, Maja Primic Žakelj, Rafael Fernández-Delgado, Marisa L Vicente Raneda, En…

MaleCàncer en els infantsTime FactorsCancer in children0302 clinical medicineRisk FactorsNeoplasms030212 general & internal medicineRegistriesAge of OnsetChildmedia_commoneducation.field_of_studyCancer in adolescenceIncidence (epidemiology)Incidence3. Good healthEuropeOncology030220 oncology & carcinogenesisRegional studiesChild PreschoolFemale2730 OncologyAdolescentPopulationChildhood cancerSocio-culturale610 Medicine & healthRisk AssessmentArticle03 medical and health sciencesYoung AdultAge DistributionSDG 3 - Good Health and Well-beingmedicinemedia_common.cataloged_instanceHumansCàncer en els adolescentsEuropean unioneducationbusiness.industryInfant NewbornCancerInfantHealth Status Disparities10060 Epidemiology Biostatistics and Prevention Institute (EBPI)medicine.diseasePopulation based studyCancer incidencebusinessDemography
researchProduct

Treatment challenges in and outside a network setting: Head and neck cancers.

2019

Head and neck cancer (HNC) is a rare disease that can affect different sites and is characterized by variable incidence and 5-year survival rates across Europe. Multiple factors need to be considered when choosing the most appropriate treatment for HNC patients, such as age, comorbidities, social issues, and especially whether to prefer surgery or radiation-based protocols. Given the complexity of this scenario, the creation of a highly specialized multidisciplinary team is recommended to guarantee the best oncological outcome and prevent or adequately treat any adverse effect. Data from literature suggest that the multidisciplinary team-based approach is beneficial for HNC patients and lea…

0301 basic medicinemedicine.medical_specialtySocio-culturaleSocial issuesMultidisciplinary team03 medical and health sciencesTherapeutic approach0302 clinical medicineRare DiseasesMultidisciplinary approachmedicineHumansAdverse effectIntensive care medicineHead and neck cancerReferral and ConsultationPatient Care TeamEuropean reference networks joint action of rare cancers ; Head and neck cancer ; Multidisciplinary team ; Rare diseasebusiness.industryHead and Neck NeoplasmHead and neck cancerEuropean reference networks joint action of rare cancersGeneral MedicineMultidisciplinary teammedicine.diseaseEurope030104 developmental biologyClinical researchOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisEuropean reference networks joint action of rare cancerSurgerybusinessEuropean reference networks joint action of rare cancers; Head and neck cancer; Multidisciplinary team; Rare disease; Surgery; OncologyRare diseaseDelivery of Health CareRare diseaseHumanEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Estimation de l’incidence des hémopathies malignes en France entre 1980 et 2012

2016

International audience; BACKGROUND:The classification of hematological malignancies (HMs) has changed in recent decades. For the first time, the French network of cancer registries (Francim) provides estimates for incidence and trends of HM in France between 1980 and 2012 for major HM subtypes.METHODS:Incidence was directly estimated by modeling the incidence rates measured in the cancer registry area. For each HM subtype, a "usable incidence period" was defined a priori, corresponding to the years for which all the registries collected them in a homogeneous way. For both sexes and each HM subtype, age-period-cohort models were used to estimate national incidence trends.RESULTS:Overall in F…

AdultMaleOncologyPediatricsmedicine.medical_specialtyRegistryAdolescentEpidemiologyChronic lymphocytic leukemiaFollicular lymphoma[SDV.CAN]Life Sciences [q-bio]/Cancer[ SDV.CAN ] Life Sciences [q-bio]/CancerHematological malignanciesYoung Adult03 medical and health sciences0302 clinical medicineNeoplasmsInternal medicinemedicineHumansRegistriesAgedAged 80 and overbusiness.industryMyelodysplastic syndromesIncidence (epidemiology)IncidencePublic Health Environmental and Occupational HealthCancer[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieHémopathies malignesMiddle AgedPlasma cell neoplasmmedicine.disease3. Good healthLymphomaCancer registryTendancesHematologic Neoplasms030220 oncology & carcinogenesisFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFranceTrendsbusinessRegistre de population030215 immunology
researchProduct

Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours

2019

Pancreatic Neuroendocrine Neoplasms comprise a group of rare tumours with special biology, an often indolent behaviour and particular diagnostic and therapeutic requirements. The specialized biochemical tests and radiological investigations, the complexity of surgical options and the variety of medical treatments that require individual tailoring, mandate a multidisciplinary approach that can be optimally achieved through an organized network. The present study describes currents concepts in the management of these tumours as well as an insight into the challenges of delivering the pathway in and outside a Network.

Liver metastasemedicine.medical_specialtyPathologySocio-culturale03 medical and health sciencesLiver metastasesRare Diseases0302 clinical medicineLiver metastases ; Neuroendocrine tumours ; Pancreas ; Rare cancersNeuroendocrine tumoursMultidisciplinary approachRare DiseaseNeuroendocrine tumourHumansMedicinePancreaRare cancersPrecision MedicineIntensive care medicinePancreasLiver metastases Neuroendocrine tumours Pancreas Rare cancersPatient Care Teambusiness.industryPancreatic NeoplasmRare cancerGeneral MedicinePancreatic NeoplasmsSurvival RateNeuroendocrine TumorsLiver metastases; Neuroendocrine tumours; Pancreas; Rare cancers; Surgery; OncologyOncology030220 oncology & carcinogenesisMandate030211 gastroenterology & hepatologySurgerybusinessNeuroendocrine TumorDelivery of Health CareHuman
researchProduct

Splenic Marginal Zone Lymphoma: French Registries Population-Based Treatment and Survival Analyses (2002-2014)

2020

Background. Splenic Marginal Zone Lymphoma (SMZL) is a rare indolent B-cell lymphoma characterized by a massive splenomegaly and a moderate lymphocytosis. There is no standard of care for SMZL so far. The treatment is indicated if constitutional symptoms, massive splenomegaly and/or cytopenia, after a watch and wait period that is highly variable. Rituximab with or without chemotherapy, chemotherapy, and splenectomy are valid treatment approaches. Our objectives were to describe the characteristics of the patients with SMZL retrospectively collected from a French population database, to analyze the treatments received in first line (Tt1) and in second line (Tt2) in term of efficacy, and to …

medicine.medical_specialtyCytopeniaLymphocytosisbusiness.industryConstitutional symptomsmedicine.medical_treatmentImmunologySplenectomyCell BiologyHematologymedicine.diseaseBiochemistryLymphomaInternal medicinemedicineRituximabSplenic marginal zone lymphomaStage (cooking)medicine.symptombusinessmedicine.drugBlood
researchProduct

Epidemiology of Mantle Cell Lymphoma: A Population-Based Study in France

2011

Abstract Abstract 5222 Introduction: Mantle cell lymphoma (MCL) is an aggressive and rare B-cell lymphoma entity representing around 5–8% of non-Hodgkin's lymphomas in adults. To our knowledge no data is available on the epidemiology of MCL in France. We aimed to describe incidence, survival and main clinical characteristics of MCL in a French population. Methods: Patients diagnosed with MCL were identified in three administrative areas covered by an haematological malignancies registry: the Côte d'Or (from 1988 to 2008), the Basse-Normandie (from 1997 to 2006) and the Gironde (from 2002 to 2006). Main clinical features and management characteristics were collected. World age-standardised …

education.field_of_studyPediatricsmedicine.medical_specialtyRelative survivalbusiness.industryIncidence (epidemiology)ImmunologyPopulationCell BiologyHematologymedicine.diseaseBiochemistryLymphomaInternational Prognostic IndexEpidemiologymedicineMantle cell lymphomaRituximabeducationbusinessmedicine.drugBlood
researchProduct

Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France.

2012

Long-term population-based survival data detailed by cancer subtype are important to measure the overall outcomes of malignancy managements. We provide net survival estimates at 1, 3, 5 and 10-year postdiagnosis on 37,549 hematological malignancy (HM) patients whose ages were >15 years, diagnosed between 1989 and 2004 and actively followed until 2008 by French population-based cancer registries. These are, to our knowledge, the first unbiased estimates of 10-year net survival in HMs detailed by subtypes. HMs were classified according to the International Classification of Diseases-Oncology 3. Net survival was estimated with the unbiased Pohar-Perme method. The results are reported by sex an…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulationFollicular lymphomaMalignancyAge DistributionBiasInternal medicinemedicineHumansRegistriesSex DistributioneducationAgededucation.field_of_studyLeukemiaModels Statisticalbusiness.industryMortality rateLymphoma Non-HodgkinCancerMiddle Agedmedicine.diseasePrognosisHodgkin DiseaseLymphomaCancer registryOncologyHematologic NeoplasmsMyelodysplastic SyndromesImmunologyFemaleFrancebusinessChronic myelogenous leukemiaInternational journal of cancer
researchProduct

Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based study

2015

BACKGROUND: Significant advances in the management of patients with lymphoid and myeloid malignancies entered clinical practice in the early 2000's. The EUROCARE-5 study database provides an opportunity to assess the impact of these changes at the population level by country in Europe. We provide survival estimates for clinically relevant haematological malignancies (HM), using the International Classification of Diseases for Oncology 3, by country, gender and age in Europe. METHODS: We estimated age-standardised relative survival using the complete cohort approach for 625, 000 adult patients diagnosed in 2000-2007 and followed up to 2008. Survival information was provided by 89 participati…

OncologyCancer registry; Europe; Hodgkin lymphoma; Leukaemia; Lymphoma; Multiple myeloma; Non-Hodgkin lymphoma; Relative survivalCancer Researcheducation.field_of_studymedicine.medical_specialtyMyeloidRelative survivalbusiness.industryPopulationFollicular lymphomaPlasma cell neoplasmmedicine.diseaseLymphomaCancer registrymedicine.anatomical_structureOncologyhemic and lymphatic diseasesInternal medicineImmunologyMedicineeducationbusinessInternational Classification of Diseases for OncologyEuropean Journal of Cancer
researchProduct

Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from th…

2013

International audience; BACKGROUND: Lymphoma occurring in patients aged 90 or older is not uncommon, and its incidence is expected to increase over time. Management of these patients is difficult given their underlying fragility and the lack of information regarding this population. PATIENTS AND METHODS: We retrospectively analyzed 234 patients diagnosed with lymphoma at the age of 90 years or older (90+) between 1990 and 2012 to describe their characteristics, management, outcomes and prognostic factors. RESULTS: The median age was 92 years; 88% were B-cell lymphomas consisting mainly in diffuse large B-cell lymphoma. The median overall survival (OS) was 7.2 months (range, 0-92 months) for…

Malemedicine.medical_specialtyPalliative careSurvivalPopulation[SDV.CAN]Life Sciences [q-bio]/Cancerlymphoma[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/Cancerimmune system diseasesInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHypoalbuminemiaeducationSerum Albumin030304 developmental biologyCause of deathRetrospective StudiesAged 80 and over0303 health scienceseducation.field_of_studypalliative carebusiness.industryIncidence (epidemiology)IncidenceLymphoma Non-HodgkinHematologymedicine.diseasePrognosisComorbidity3. Good healthLymphomaSurgeryaged 80 and overcomorbidityOncology030220 oncology & carcinogenesisFemaleLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphoma
researchProduct

Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes

2021

Aim: Recessive genetic variation is thought to play a role in non-Hodgkin lymphoma (NHL) etiology. Runs of homozygosity (ROH), defined based on long, continuous segments of homozygous SNPs, can be used to estimate both measured and unmeasured recessive genetic variation. We sought to examine genome-wide homozygosity and NHL risk.Methods: We used data from eight genome-wide association studies of four common NHL subtypes: 3061 chronic lymphocytic leukemia (CLL), 3814 diffuse large B-cell lymphoma (DLBCL), 2784 follicular lymphoma (FL), and 808 marginal zone lymphoma (MZL) cases, as well as 9374 controls. We examined the effect of homozygous variation on risk by: (1) estimating the fraction o…

GeneticsChronic lymphocytic leukemiadiffuse large B-cell lymphomaFollicular lymphomaSingle-nucleotide polymorphismRuns of HomozygosityBiologymedicine.diseasemarginal zone lymphomaArticlefollicular lymphomaimmune system diseaseshemic and lymphatic diseasesGenetic variationmedicinechronic lymphocytic leukemiahomozygosityDiffuse large B-cell lymphomaInbreedingNon-Hodgkin lymphomaGenetic associationJournal of Translational Genetics and Genomics
researchProduct

InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future dir…

2010

Abstract After publication of the updated World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues in 2008, the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) now presents an update of the hierarchical classification of lymphoid neoplasms for epidemiologic research based on the 2001 WHO classification, which we published in 2007. The updated hierarchical classification incorporates all of the major and provisional entities in the 2008 WHO classification, including newly defined entities based on age, site, certain infections, and molecular characteristics, as well as borderline categories, early and “in situ” …

medicine.medical_specialtyPathologyLymphoid NeoplasiaLymphomabusiness.industryImmunologyMEDLINELymphoproliferative disordersCell BiologyHematologyComputational biologyWorld Health Organizationmedicine.diseaseBiochemistryWorld healthLymphomaEpidemiologic StudiesEpidemiologymedicineHumansLymphoid neoplasmsEpidemiologic researchbusinessWho classificationSocieties MedicalBlood
researchProduct

A genome-wide association study of marginal zone lymphoma shows association to the HLA region

2015

Marginal zone lymphoma (MZL) is the third most common subtype of B-cell non-Hodgkin lymphoma. Here we perform a two-stage GWAS of 1,281 MZL cases and 7,127 controls of European ancestry and identify two independent loci near BTNL2 (rs9461741, P=3.95 × 10−15) and HLA-B (rs2922994, P=2.43 × 10−9) in the HLA region significantly associated with MZL risk. This is the first evidence that genetic variation in the major histocompatibility complex influences MZL susceptibility.

Medicin och hälsovetenskapLymphomaResearch Support U.S. Gov't P.H.S.Follicular lymphomaGeneral Physics and AstronomyGenome-wide association studyMarginal ZoneP.H.S.Medical and Health SciencesMajor Histocompatibility ComplexPolymorphism (computer science)Non-U.S. Gov'tGENE-EXPRESSIONCELL DEVELOPMENTGeneticsMultidisciplinaryMembrane GlycoproteinsResearch Support Non-U.S. Gov'tSingle NucleotideMarginal zone3. Good healthMultidisciplinary SciencesScience & Technology - Other TopicsNON-HODGKIN-LYMPHOMASUSCEPTIBILITY LOCIGenotypeCèl·lules BEuropean Continental Ancestry GroupEPIDEMIOLOGIC RESEARCHHuman leukocyte antigenBiologyResearch SupportPolymorphism Single NucleotideCLASSIFICATIONGeneral Biochemistry Genetics and Molecular BiologyWhite PeopleArticleN.I.H.Research Support N.I.H. ExtramuralMarginal zone lymphomaMD MultidisciplinaryGenetic variationmedicineJournal ArticleHumansPolymorphismGASTRIC LYMPHOMAIntramuralB cellsScience & TechnologyButyrophilinsGastric lymphomaB-CellExtramuralComputational BiologyGeneral ChemistryLymphoma B-Cell Marginal ZoneResearch Support N.I.H. Intramuralmedicine.diseaseRISK LOCIRHEUMATOID-ARTHRITISLymphomaMalaltia de HodgkinImmunologyU.S. Gov'tHodgkin's diseaseFOLLICULAR LYMPHOMAGenome-Wide Association Study
researchProduct

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes

2018

Abstract A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of “heterozygote advantage” regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL…

Male0301 basic medicineHeterozygoteCancer Researchmedicine.medical_specialtySUSCEPTIBILITY LOCIChronic lymphocytic leukemiaEPIDEMIOLOGIC RESEARCHGenome-wide association studyHuman leukocyte antigenBiologyCLASSIFICATIONANTIGENSArticleGenetic Heterogeneity03 medical and health sciencesimmune system diseaseshemic and lymphatic diseasesInternal medicinemedicineINTERLYMPHHumans1112 Oncology and CarcinogenesisOncology & CarcinogenesisProspective StudiesGENOME-WIDE ASSOCIATIONAlleleHLA ComplexScience & TechnologyHematologyCHRONIC LYMPHOCYTIC-LEUKEMIAGenetic heterogeneityLymphoma Non-HodgkinHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHETEROZYGOTE ADVANTAGEmedicine.disease3. Good healthLymphoma030104 developmental biologyOncologyCase-Control StudiesImmunologyB-VIRUS INFECTIONFemaleLife Sciences & BiomedicineNEOPLASMSGenome-Wide Association StudyCancer Research
researchProduct

Global surveillance of trends in cancer survival 2000-14 (concord-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18…

2018

Eser, Sultan (Balikesir Author)

0301 basic medicineUniversal Health Coveragepopulation-based registriesRelative SurvivalSettore MED/42 - Igiene Generale E ApplicataCancer -- TreatmentHumans; Neoplasms; Population Surveillance; Registries; Survival Rate; Medicine (all)0302 clinical medicineNeoplasmsRegistriescancer survivaleducation.field_of_studyRelative survivalMedicine (all)EPICENEGeneral Medicine3. Good healthSurvival Ratetrend030220 oncology & carcinogenesisPopulation SurveillancePublic-Healthcancer surveillanceLiver cancersurvival ; cancer registry ; CONCORD-3CureChildhood-Cancermedicine.medical_specialtypopulation-based cancer registriesWomens CancersPopulationMedicine (all)cancer survival population-based cancer registriesSocio-culturaleUnited-StatessurvivalArticle03 medical and health sciencesBreast cancerCancer epidemiologymedicineHumansNordic-CountriesCancer -- MortalityeducationSurvival rateCancer preventionAlternative Approachbusiness.industryPublic healthCancerCancer -- Patients -- Long-term caremedicine.disease030104 developmental biologyHigh-Income Countries[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessDemography
researchProduct

Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes.

2019

International audience; Epidemiologic studies show an increased risk of non-Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen-stimulation in one disease leads to another. Here we assess shared genetic risk in genome-wide-association-studies (GWAS). Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (a) description of regional g…

OncologyMaleMultifactorial InheritanceLymphomaEpidemiologyChronic lymphocytic leukemiaFollicular lymphomaGenome-wide association studyDiseaseNeurodegenerativemeta-analysiimmune system diseasesHLA AntigensRisk Factorshemic and lymphatic diseases2.1 Biological and endogenous factorsHLA AntigenAetiologyGenetics (clinical)CancerAllele0303 health sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyLymphoma Non-Hodgkinnon-Hodgkin lymphoma030305 genetics & hereditySingle NucleotideHematologyMiddle Aged3. Good healthnon-Hodgkin lymphoma.Public Health and Health ServicesFemaleHumanmedicine.medical_specialtyautoimmune disease; genome-wide association study; meta-analysis; non-Hodgkin lymphoma; Alleles; Autoimmune Diseases; Female; HLA Antigens; Humans; Lymphoma Non-Hodgkin; Male; Middle Aged; Multifactorial Inheritance; Polymorphism Single Nucleotide; Risk Factors; Genetic Predisposition to DiseaseNon-Hodgkinautoimmune diseasePolymorphism Single NucleotideArticleAutoimmune Diseases03 medical and health sciencesRare DiseasesInternal medicineGenetic variationmedicineGeneticsHumansGenetic Predisposition to DiseasePolymorphismAlleles030304 developmental biologyAutoimmune diseasegenome-wide association studybusiness.industryMultiple sclerosisRisk FactorArthritisInflammatory and immune systemHuman Genomemedicine.diseaseLymphomaBrain Disordersmeta-analysisbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Geographical Disparities in Multiple Myeloma Survival in Three French Regions

2016

Abstract Introduction: Within the past decade, new therapeutic agents for Multiple Myeloma (MM) have improved survival of patients included in clinical trials. The aim of this study was to measure and compare characteristics and survival of patients with MM in different French regions in the general population. Methods: All incident cases with MM (ICD-O-3 codes, 9732/3 and) between January 1, 2008 and December 31, 2009 in the French population-based Hematological Malignancies registries (Calvados, Côte d'Or and Gironde) were included. The end point of follow-up was January 1, 2015. Specific clinical information was recorded from clinical charts. Incidence rates were calculated using estimat…

education.field_of_studyPediatricsmedicine.medical_specialtyMultivariate analysisAnemiabusiness.industryImmunologyPopulationImproved survivalCell BiologyHematologymedicine.diseaseBiochemistryClinical trialmedicinebusinesseducationNet SurvivalSex ratioMultiple myelomaDemographyBlood
researchProduct

Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis

2018

IF 15.132 (2017); International audience; Inherited loci have been found to be associated with risk of chronic lymphocytic leukemia (CLL). A combined polygenic risk score (PRS) of representative single nucleotide polymorphisms (SNPs) from these loci may improve risk prediction over individual SNPs. Herein, we evaluated the association of a PRS with CLL risk and its precursor, monoclonal B-cell lymphocytosis (MBL). We assessed its validity and discriminative ability in an independent sample and evaluated effect modification and confounding by family history (FH) of hematological cancers. For discovery, we pooled genotype data on 41 representative SNPs from 1499 CLL and 2459 controls from the…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyLymphocytosisClinical Trials and ObservationsChronic lymphocytic leukemiaImmunologySingle-nucleotide polymorphism[SDV.CAN]Life Sciences [q-bio]/CancerLymphocytosisPolymorphism Single NucleotideBiochemistry03 medical and health sciences0302 clinical medicineRisk Factorsimmune system diseasesInternal medicinehemic and lymphatic diseasesGenotypeOdds RatiomedicineHumansGenetic Predisposition to Disease10. No inequalityAgedAged 80 and overB-Lymphocytesbusiness.industryConfoundingCell BiologyHematologyOdds ratioMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-Cell3. Good health030104 developmental biologyGenetic epidemiologyGenetic Loci030220 oncology & carcinogenesisMonoclonal B-cell lymphocytosisFemalemedicine.symptombusiness
researchProduct

Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymp…

2013

Kamper-Jorgensen, M Rostgaard, K Glaser, S L Zahm, S H Cozen, W Smedby, K E Sanjose, S Chang, E T Zheng, T La Vecchia, C Serraino, D Monnereau, A Kane, E V Miligi, L Vineis, P Spinelli, J J McLaughlin, J R Pahwa, P Dosman, J A Vornanen, M Foretova, L Maynadie, M Staines, A Becker, N Nieters, A Brennan, P Boffetta, P Cocco, P Hjalgrim, H eng 5 ROI CA69269/CA/NCI NIH HHS/ Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't England 2013/06/22 06:00 Ann Oncol. 2013 Sep;24(9):2245-55. doi: 10.1093/annonc/mdt218. Epub 2013 Jun 19.; International audience; BACKGROUND: The etiology of Hodgkin lymphoma (HL) remains incompletely characterized. Studies of the association between smok…

AdultMaleRiskOncologyEpstein-Barr Virus InfectionsHerpesvirus 4 Humanmedicine.medical_specialtyAdolescentReviewscigarette smokingYoung AdultNodular sclerosisRisk FactorsInternal medicineEpidemiologycase–controlmedicineHumansEpstein–Barr viruindividual patient data meta-analysisYoung adultAgedAged 80 and overbusiness.industrySmokingConfoundingCase-control studyTobacco Use DisorderHematologyOdds ratioMiddle Agedmedicine.diseaseHodgkin DiseaseLymphomaSocial ClassOncologyCase-Control StudiesImmunologyEtiologyFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieepidemiologybusinessHodgkin lymphomaAnnals of Oncology
researchProduct

Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting.

2017

The management of patients with mesothelioma and thymic malignancy requires continuous multidisciplinary expertise at any step of the disease. A dramatic improvement in our knowledge has occurred in the last few years, through the development of databases, translational research programs, and clinical trials. Access to innovative strategies represents a major challenge, as there is a lack of funding for clinical research in rare cancers and their rarity precludes the design of robust clinical trials that could lead to specific approval of drugs. In this context, patient-centered initiatives, such as the establishment of dedicated networks, are warranted. International societies, such as IMI…

0301 basic medicineMesotheliomamedicine.medical_specialtyInternational CooperationPleural NeoplasmsMEDLINESocio-culturaleContext (language use)Translational researchDiseaseSocial Networking03 medical and health sciences0302 clinical medicineMultidisciplinary approachMedicineHumansMesotheliomaPleural NeoplasmIntensive care medicinebusiness.industryGeneral MedicineThymus Neoplasmsmedicine.diseaseClinical trialEuropeSurvival Rate030104 developmental biologyClinical researchOncology030220 oncology & carcinogenesisSurgery; OncologySurgerybusinessDelivery of Health Caremesothelioma thymic tumours clinical trialsHumanEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region.

2014

Genome-wide association studies (GWASs) of follicular lymphoma (FL) have previously identified human leukocyte antigen (HLA) gene variants. To identify additional FL susceptibility loci, we conducted a large-scale two-stage GWAS in 4,523 case subjects and 13,344 control subjects of European ancestry. Five non-HLA loci were associated with FL risk: 11q23.3 (rs4938573, p = 5.79 × 10 -20) near CXCR5; 11q24.3 (rs4937362, p = 6.76 × 10 -11) near ETS1; 3q28 (rs6444305, p = 1.10 × 10 -10) in LPP; 18q21.33 (rs17749561, p = 8.28 × 10 -10) near BCL2; and 8q24.21 (rs13254990, p = 1.06 × 10 -8) near PVT1. In an analysis of the HLA region, we identified four linked HLA-DRß1 multiallelic amino acids at p…

EXPRESSIONFollicular lymphomaSingle-nucleotide polymorphismGenome-wide association studyHuman leukocyte antigenBiologyVARIANTSPolymorphism Single Nucleotidefollicular lymphomaHLA AntigensPolymorphism (computer science)ReportCLASS-IRESOURCEBiomarkers TumorGeneticsmedicineChromosomes HumanHumansTOOLGenetic Predisposition to DiseaseGenetics(clinical)PEPTIDEAlleleLymphoma FollicularAllelesGenetics (clinical)Genetic associationSNPSGeneticsRISKGenome-wide associationHaplotypemedicine.diseaseHLAHaplotypesCase-Control StudiesUNIVERSITYSETGenome-Wide Association Study
researchProduct

Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009.

2014

The treatment of chronic myeloid leukemia (CML) has seen several major advances over the past 30 years, notably with the introduction of interferon followed by Bcr-Abl tyrosine kinase inhibitors. We analyzed trends in the incidence of CML and patient survival in France. All cases recorded in five population-based registries between 1980 and 2009 were included. European (ESR) and world (WSR) standardized incidence rates as well as relative survival (RS) rates were estimated. We analyzed data for 781 patients (9863/3: 13.6%; 9875/3: 82.2%; 9876/3: 4.2%). ESR was 1.02 [95% confidence interval (CI) = 0.93-1.11] and WSR was 0.81 [95% CI = 0.72-0.90]. The five RS rates among patients with Philade…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulation03 medical and health sciencesYoung Adult0302 clinical medicinehemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansRegistrieseducationChildSurvival analysisAgedAged 80 and overeducation.field_of_studyPhiladelphia Chromosome PositiveRelative survivalbusiness.industryIncidence (epidemiology)IncidenceInfant NewbornMyeloid leukemiaCancerInfantHematologyMiddle Agedmedicine.diseaseSurvival AnalysisConfidence interval3. Good healthOncology030220 oncology & carcinogenesisChild PreschoolPopulation SurveillanceImmunologyDisease ProgressionFemaleFrancebusiness030215 immunologyFollow-Up StudiesLeukemialymphoma
researchProduct

Genetically Determined Height and Risk of Non-hodgkin Lymphoma

2020

Although the evidence is not consistent, epidemiologic studies have suggested that taller adult height may be associated with an increased risk of some non-Hodgkin lymphoma (NHL) subtypes. Height is largely determined by genetic factors, but how these genetic factors may contribute to NHL risk is unknown. We investigated the relationship between genetic determinants of height and NHL risk using data from eight genome-wide association studies (GWAS) comprising 10,629 NHL cases, including 3,857 diffuse large B-cell lymphoma (DLBCL), 2,847 follicular lymphoma (FL), 3,100 chronic lymphocytic leukemia (CLL), and 825 marginal zone lymphoma (MZL) cases, and 9,505 controls of European ancestry. We …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyChronic lymphocytic leukemiaFollicular lymphomadiffuse large B-cell lymphomaSingle-nucleotide polymorphismGenome-wide association studylcsh:RC254-28203 medical and health sciences0302 clinical medicinefollicular lymphomaimmune system diseasesInternal medicinehemic and lymphatic diseasesGeneticsMedicineLeucèmia limfocítica crònicageneticsOriginal ResearchGenetic associationCancer och onkologibusiness.industrynon-Hodgkin lymphomaOdds ratiomedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmarginal zone lymphomaLymphomaMalaltia de Hodgkin030104 developmental biologyOncologyCancer and Oncology030220 oncology & carcinogenesispolygenic risk scorediffuse large B-celllymphomachronic lymphocytic leukemiaChronic lymphocytic leukemiaHodgkin's diseasegeneticbusinessDiffuse large B-cell lymphomaGenèticaheightFrontiers in Oncology
researchProduct

Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study

2017

Background: Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare cancers is scant. The RARECARE project defined rare cancers as those with an annual incidence of less than six per 100 000 people in European Union (EU). We updated the estimates of the burden of rare cancers in Europe, their time trends in incidence and survival, and provide information about centralisation of treatments in seven European countries. Methods: We analysed data from 94 cancer registries for more than 2 million rare cancer diagnoses, to estimate European incidence and survival in 2000–07 and the corresponding time trends during 1995–2007. Incidence was calcu…

Male0301 basic medicinePathologypopulation-based registriesCancer Care Facilities; Delivery of Health Care; Europe; Female; Hospitalization; Humans; Incidence; Male; Neoplasms; Rare Diseases; Registries; Survival Rate; Oncology0302 clinical medicineNeoplasmsMedicineRegistriesmedia_commonTumors -- Treatment -- Europeeducation.field_of_studyRelative survivalIncidenceIncidence (epidemiology)RARECARE projectEuropeHospitalizationSurvival RateOncology030220 oncology & carcinogenesis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalemedicine.medical_specialtyHealth surveysPopulationSocio-culturaleCancer Care Facilities03 medical and health sciencesRare DiseasesSDG 3 - Good Health and Well-beingHumansmedia_common.cataloged_instanceCancer -- MortalityRisk factorEuropean unioneducationSurvival rateOncology cancer burden incidence rare cancerpopulation-based registriesrare cancers cancer registry RARECAREbusiness.industryRare cancerCancer -- Patients -- Long-term careCancer registry030104 developmental biologycancer burdenbusinessDelivery of Health CareDemographyRare disease
researchProduct

Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000–14 (CONCO…

2022

BACKGROUND Leukaemias comprise a heterogenous group of haematological malignancies. In CONCORD-3, we analysed data for children (aged 0-14 years) and adults (aged 15-99 years) diagnosed with a haematological malignancy during 2000-14 in 61 countries. Here, we aimed to examine worldwide trends in survival from leukaemia, by age and morphology, in young patients (aged 0-24 years). METHODS We analysed data from 258 population-based cancer registries in 61 countries participating in CONCORD-3 that submitted data on patients diagnosed with leukaemia. We grouped patients by age as children (0-14 years), adolescents (15-19 years), and young adults (20-24 years). We categorised leukaemia subtypes a…

AdolescentAustralia610 Medicine & healthlymphomaSettore MED/42 - Igiene Generale E ApplicatasurvivalUnited StatesEuropeLeukemia Myeloid AcuteYoung Adultchildrenpopulation-based/cancer registry360 Social problems & social servicessurvival leukemia cancer registryHematologic NeoplasmsleukaemiaPediatrics Perinatology and Child HealthDevelopmental and Educational PsychologycancerHumansRegistrieshaematological malignancy610 Medicine & healthChild360 Social problems & social services
researchProduct

Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma.

2015

Non-Hodgkin lymphoma (NHL) represents a heterogeneous group of diseases that are known to carry a considerable risk of second primary cancer (SPC). However, little attention has been paid to SPC risk assessment according to NHL subtypes. Data from 10 French population-based cancer registries were used to establish a cohort of 7546 patients with a first diagnosis of NHL (eight subtypes) between 1989 and 2004. Standardized incidence ratios (SIRs) of metachronous SPC were estimated. Among the 7546 patients diagnosed with a NHL, the overall SPC risk was 25% higher than that in the reference population (SIR = 1.25, 95% confidence interval 1.15–1.36). In univariate analysis, the SPC risk differed…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyanimal structuresMultivariate analysisAdolescentPopulationRisk AssessmentCohort StudiesYoung Adultimmune system diseaseshemic and lymphatic diseasesInternal medicineEpidemiologymedicineHumansRegistrieseducationChildAgedAged 80 and overUnivariate analysiseducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceLymphoma Non-HodgkinfungiAge FactorsInfant NewbornCancerInfantNeoplasms Second PrimaryHematologyMiddle Agedmedicine.diseaseOncologyChild PreschoolPopulation SurveillanceCohortImmunologyFemaleFranceRisk assessmentbusinessFollow-Up StudiesLeukemialymphoma
researchProduct

Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types

2015

BACKGROUND: Studies of related individuals have consistently demonstrated notable familial aggregation of cancer. We aim to estimate the heritability and genetic correlation attributable to the additive effects of common single-nucleotide polymorphisms (SNPs) for cancer at 13 anatomical sites.METHODS: Between 2007 and 2014, the US National Cancer Institute has generated data from genome-wide association studies (GWAS) for 49 492 cancer case patients and 34 131 control patients. We apply novel mixed model methodology (GCTA) to this GWAS data to estimate the heritability of individual cancers, as well as the proportion of heritability attributable to cigarette smoking in smoking-related cance…

MaleCancer ResearchLung NeoplasmsLymphomaGenome-wide association studyPolymorphism (computer science)NeoplasmsMedicineChronicGeneticsOsteosarcomaOncology And CarcinogenesisLeukemiaSmokingFamily aggregationSingle NucleotideMiddle AgedFamilial riskDiffuseKidney NeoplasmsLymphocyticOncologyAdult; Aged; Asian Continental Ancestry Group; Bone Neoplasms; European Continental Ancestry Group; Female; Humans; Kidney Neoplasms; Leukemia Lymphocytic Chronic B-Cell; Lung Neoplasms; Lymphoma Large B-Cell Diffuse; Male; Middle Aged; Neoplasms; Osteosarcoma; Polymorphism Single Nucleotide; Smoking; Testicular Neoplasms; Tissue Array Analysis; Urinary Bladder Neoplasms; Genetic Predisposition to Disease; Genome-Wide Association StudyFemaleLymphoma Large B-Cell DiffuseAdultAsian Continental Ancestry GroupEuropean Continental Ancestry Group/Bone NeoplasmsPolymorphism Single NucleotideGenetic correlationTesticular NeoplasmsLarge B-CellHumansGenetic Predisposition to DiseaseOncology & CarcinogenesisPolymorphismAgedbusiness.industryExtramuralB-CellCancerHeritabilityGenome-wide association studies for thirteen cancer typesmedicine.diseaseLeukemia Lymphocytic Chronic B-CellUrinary Bladder NeoplasmsTissue Array AnalysisbusinessGenome-Wide Association StudyJournal of the National Cancer Institute
researchProduct

Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia

2016

Chronic lymphocytic leukemia (CLL) is a common lymphoid malignancy with strong heritability. To further understand the genetic susceptibility for CLL and identify common loci associated with risk, we conducted a meta-analysis of four genome-wide association studies (GWAS) composed of 3,100 cases and 7,667 controls with follow-up replication in 1,958 cases and 5,530 controls. Here we report three new loci at 3p24.1 (rs9880772, EOMES, P=2.55 × 10−11), 6p25.2 (rs73718779, SERPINB6, P=1.97 × 10−8) and 3q28 (rs9815073, LPP, P=3.62 × 10−8), as well as a new independent SNP at the known 2q13 locus (rs9308731, BCL2L11, P=1.00 × 10−11) in the combined analysis. We find suggestive evidence (P<5 × 10−…

0301 basic medicineMedicin och hälsovetenskapChronic lymphocytic leukemiaGeneral Physics and AstronomyGenome-wide association studyVARIANTSMedical and Health SciencesMalalties hereditàries[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyChronicGeneticsRISKLeukemiaMultidisciplinaryBANK1VDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin sosialmedisin: 801Bcl-2-Like Protein 11QAdaptor Proteins[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologySingle NucleotideLymphocytic3. Good healthPRIORITIZATIONMultidisciplinary SciencesLeukemiamedicine.anatomical_structureScience & Technology - Other TopicsTRANSCRIPTION FACTOR EOMESODERMINGenetic disordersEXPRESSIONSUSCEPTIBILITY LOCIScienceEuropean Continental Ancestry GroupFAS GENE-MUTATIONSLocus (genetics)BiologyPolymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyCLASSIFICATIONWhite PeopleArticle03 medical and health sciencesProto-Oncogene ProteinsMD MultidisciplinarymedicineGenetic predispositionSNPHumansLeucèmia limfocítica crònicaGenetic Predisposition to DiseasePolymorphismB cellSerpinsGenetic associationAdaptor Proteins Signal TransducingScience & TechnologySignal TransducingB-CellMembrane ProteinsGeneral Chemistrymedicine.diseaseLeukemia Lymphocytic Chronic B-Cell030104 developmental biologyChronic lymphocytic leukemiaVDP::Medical disciplines: 700::Health sciences: 800::Community medicine Social medicine: 801Apoptosis Regulatory ProteinsT-Box Domain ProteinsFOLLICULAR LYMPHOMAGenome-Wide Association Study
researchProduct

Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma

2014

Diffuse large B cell lymphoma (DLBCL) is the most common lymphoma subtype and is clinically aggressive. To identify genetic susceptibility loci for DLBCL, we conducted a meta-analysis of 3 new genome-wide association studies (GWAS) and 1 previous scan, totaling 3,857 cases and 7,666 controls of European ancestry, with additional genotyping of 9 promising SNPs in 1,359 cases and 4,557 controls. In our multi-stage analysis, five independent SNPs in four loci achieved genome-wide significance marked by rs116446171 at 6p25.3 (EXOC2; P = 2.33 × 10 '21), rs2523607 at 6p21.33 (HLA-B; P = 2.40 × 10 '10), rs79480871 at 2p23.3 (NCOA1; P = 4.23 × 10 '8) and two independent SNPs, rs13255292 and rs47336…

LimfomesGenotypeChronic lymphocytic leukemiaCèl·lules BQuantitative Trait LociPopulationFollicular lymphomaGenome-wide association studySingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideArticleWhite PeopleGeneticsGenetic predispositionmedicineHumansGenetic Predisposition to DiseaseeducationGenetic associationGeneticsLikelihood Functionseducation.field_of_studyB cellsChromosome MappingComputational Biologymedicine.diseaseGenetic Locilarge B cell lymphoma (DLBCL)LymphomasLymphoma Large B-Cell DiffuseDiffuse large B-cell lymphomaGenome-Wide Association Study
researchProduct

Second Cancer Incidence Among Chronic Lymphocytic Leukemia (CLL) Patients: A French Population-Based Study

2014

Abstract Introduction. The risk of developing a second primary cancer (SPC) is increased in patients with CLL. The mechanisms explaining this association could be related to lifestyle, environment, host factors or interactions or other influences. We conducted an epidemiological study based on 10 French registries and evaluated the risk of developing SPC in patients with CLL. Methods. Data from French population-based registries were used to establish a cohort of all patients diagnosed with a first cancer between 1989 and 2004 and followed-up until December 31, 2007. The person-year approach was used to estimate Standardized Incidence Ratios (SIRs) and Excess Absolute Risks (EARs) of metach…

Oncologymedicine.medical_specialtyeducation.field_of_studyAcute leukemiabusiness.industryIncidence (epidemiology)ImmunologyPopulationAbsolute risk reductionCancerCell BiologyHematologyDiseasemedicine.diseaseBiochemistryInternal medicineEpidemiologyCohortImmunologymedicineeducationbusinessBlood
researchProduct

Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: The InterLymph…

2014

Background: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are two subtypes of non-Hodgkin lymphoma. A number of studies have evaluated associations between risk factors and CLL/SLL risk. However, these associations remain inconsistent or lacked confirmation. This may be due, in part, to the inadequate sample size of CLL/SLL cases. Methods: We performed a pooled analysis of 2440 CLL/SLL cases and 15 186 controls from 13 case-control studies from Europe, North America, and Australia. We evaluated associations of medical history, family history, lifestyle, and occupational risk factors with CLL/SLL risk. Multivariate logistic regression analyses were used to estimate …

AdultMaleOncologymedicine.medical_specialtyCancer ResearchChronic lymphocytic leukemiaComorbidityArticleYoung AdultRisk FactorsOccupational ExposureInternal medicinehemic and lymphatic diseasesOdds RatiomedicineHumansMedical historyFamily historyYoung adultLife StyleAgedAged 80 and overbusiness.industryAustraliaCase-control studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-CellLymphomaEuropeOncologyCase-Control StudiesMeta-analysisNorth AmericaImmunologyFemalebusiness
researchProduct

Occupation and Risk of Non-Hodgkin Lymphoma and Its Subtypes: A Pooled Analysis from the InterLymph Consortium

2016

Background: Various occupations have been associated with an elevated risk of non-Hodgkin lymphoma (NHL), but results have been inconsistent across studies. Objectives: We investigated occupational risk of NHL and of four common NHL subtypes with particular focus on occupations of a priori interest. Methods: We conducted a pooled analysis of 10,046 cases and 12,025 controls from 10 NHL studies participating in the InterLymph Consortium. We harmonized the occupational coding using the 1968 International Standard Classification of Occupations (ISCO-1968) and grouped occupations previously associated with NHL into 25 a priori groups. Odds ratios (ORs) adjusted for center, age, and sex were det…

OncologyAdultMalemedicine.medical_specialtyAdolescentHealth Toxicology and MutagenesisMEDLINEReviewBarbering03 medical and health sciences0302 clinical medicineimmune system diseasesRisk FactorsInternal medicinehemic and lymphatic diseasesmedicineHumans030212 general & internal medicineAgedAged 80 and overbusiness.industryExtramuralPublic healthLymphoma Non-HodgkinPublic Health Environmental and Occupational HealthCase-control studyAgricultureMiddle Agedmedicine.disease030210 environmental & occupational healthSeguretat en el treballLymphomaMalaltia de HodgkinOccupational DiseasesPooled analysisMeta-analysisCase-Control StudiesTextile IndustryHodgkin lymphomaIndustrial safetyFemaleHodgkin's diseasebusinessOccupation - non-hodgkin lymphomaEnvironmental Health Perspectives
researchProduct